SOB101 is an HLA-G targeted exosomal doxorubicin,
the first broad-spectrum exosome-based anti-cancer drug derived from SOB100 platform technology, using HLA-G targeted exosomes to deliver doxorubicin for the treatment of breast cancer, ovarian cancer, pancreatic cancer, lung cancer as well as brain tumor.
Preclinical studies have demonstrated that SOB101 is more effective and safer than doxorubicin and liposomal doxorubicin, with no cardiotoxicity observed.ShineOn has completed a positive FDA Pre-IND consultation in Mar 2024.
